FrancophonIA/ELRC3.0 huggingface dataset:
English: 1 When doses are provided, they are the doses used in clinical drug-drug interaction studies.
Slovenian: 1 Kjer so navedeni odmerki, so to odmerki, ki so jih uporabljali v kliničnih študijah medsebojnega delovanja zdravil.
English: The safety of emtricitabine and tenofovir alafenamide has not been established in these patients.
Slovenian: Varnosti emtricitabina in tenofoviralafenamida pri teh bolnikih niso dokazali.
English: No dose adjustment of midazolam is required.
Slovenian: Odmerka midazolama ni treba prilagajati.
English: a n = 24 adolescents (GS-US-292-0106); n = 19 adults (GS-US-292-0102) b n = 23 adolescents (GS-US-292-0106, population PK analysis) c n = 539 (TAF) or 841 (TFV) adults (GS-US-292-0111 and GS-US-292-0104, population PK analysis)
Slovenian: a n = 24 mladostnikov (GS-US-292-0106); n = 19 odraslih (GS-US-292-0102) b n = 23 mladostnikov (GS-US-292-0106, populacijska FK-analiza) c n = 539 (TAF) ali 841 (TFV) odraslih (GS-US-292-0111 in GS-US-292-0104, populacijska FK-analiza)
English: While taking Descovy you may still develop infections or other illnesses associated with HIV infection.
Slovenian: Med jemanjem zdravila Descovy se lahko pojavijo okužbe ali druge bolezni, povezane z okužbo z virusom HIV.
English: Cmax, Cmin2
Slovenian: AUC, Cmax, Cmin2
English: Therefore, Descovy should not be used during breast-feeding.
Slovenian: Zato se zdravilo Descovy med dojenjem ne sme uporabljati.
English: No dose adjustment of Descovy is required in elderly patients (see sections 5.1 and 5.2).
Slovenian: Odmerka zdravila Descovy pri starejših bolnikih ni treba prilagoditi (glejte poglavji 5.1 in 5.2).
English: Pooled treatment outcomes at 48 and 144 weeks are shown in Table 4.
Slovenian: Združeni izidi zdravljenja v 48. in 144. tednu so prikazani v preglednici 4.
English: What Descovy is and what it is used for What you need to know before you take Descovy How to take Descovy
Slovenian: Kaj je zdravilo Descovy in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Descovy Kako jemati zdravilo Descovy Možni neželeni učinki
English: • Use effective contraception while taking Descovy.
Slovenian: • Med jemanjem zdravila Descovy morate uporabljati učinkovito kontracepcijo.
English: Maraviroc Nevirapine Raltegravir
Slovenian: maravirok nevirapin raltegravir
English: The safety and efficacy of Descovy in children younger than 12 years of age, or weighing < 35 kg, have not yet been established.
Slovenian: Pediatrična populacija Varnost in učinkovitost zdravila Descovy pri otrocih, mlajših od 12 let, ali s telesno maso < 35 kg, še nista bili dokazani.
English: The mean steady state plasma trough concentration at 24 hours post-dose was equal to or greater than the mean in vitro IC90 value for anti-HIV-1 activity.
Slovenian: Povprečna plazemska koncentracija v stanju dinamičnega ravnovesja 24 ur po odmerjanju pred naslednjim odmerkom je bila enaka ali večja kot povprečna vrednost IC90 in vitro za aktivnost proti-HIV-1.
English: Descovy comes in bottles of 30 tablets (with a silica gel desiccant that must be kept in the bottle to help protect your tablets).
Slovenian: Zdravilo Descovy je na voljo v plastenkah po 30 tablet (s silikagelskim sušilnim sredstvom, ki mora ostati v vsebniku zaradi zaščite tablet).
English: Then take the next dose as usual.
Slovenian: Nato vzemite naslednji odmerek ob svojem običajnem času.
English: There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when tenofovir disoproxil was combined with lamivudine and abacavir as well as with lamivudine and didanosine as a once daily regimen.
Slovenian: Poročali so o velikem deležu virološkega neuspeha in pojava rezistence v zgodnji fazi, ko so dizoproksiltenofovirat kombinirali z lamivudinom in abakavirjem ter lamivudinom in didanozinom z režimom odmerjanja enkrat na dan.
English: Other medicines and Descovy Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Slovenian: Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
English: E/C/F/TAF = elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate FTC = emtricitabine; TAF = tenofovir alafenamide fumarate; TFV = tenofovir N/A = not applicable
Slovenian: E/C/F/TAF = elvitegravir/kobicistat/emtricitabin/tenofoviralafenamidijev fumarat FTC = emtricitabin; TAF = tenofoviralafenamidijev fumarat; TFV = tenofovir n/v = ne velja
English: IMMUNOSUPPRESSANTS Ciclosporin
Slovenian: IMUNOSUPRESIVI ciklosporin
English: Relative to fasting conditions, the administration of tenofovir alafenamide with a high fat meal (~800 kcal, 50% fat) resulted in a decrease in tenofovir alafenamide Cmax (15-37%) and an increase in AUClast (17-77%).
Slovenian: Relativno glede na pogoje na tešče je dajanje tenofoviralafenamida z obrokom z veliko vsebnostjo maščob (~ 800 kcal, 50 % maščobe) povzročilo zmanjšanje vrednost Cmax (15-37 %) in povečanje vrednost AUClast (17-77 %) za tenofoviralafenamid.
English: Dose Descovy according to the concomitant antiretroviral (see section 4.2).
Slovenian: Zdravilo Descovy se odmerja v skladu s sočasno uporabljenimi protiretrovirusnimi zdravili (glejte poglavje 4.2).
English: The safety and efficacy of Descovy in patients with significant underlying liver disorders have not been established (see sections 4.2 and 5.2).
Slovenian: Varnost in učinkovitost zdravila Descovy pri bolnikih s pomembnejšimi sočasnimi jetrnimi boleznimi nista bili dokazani (glejte poglavji 4.2 in 5.2).
English: Adults and adolescents aged 12 years and older, weighing at least 35 kg Descovy should be administered as shown in Table 1.
Slovenian: Odrasli in mladostniki, stari 12 let in več, s telesno maso vsaj 35 kg Zdravilo Descovy je treba dajati, kot je prikazano v preglednici 1.
English: The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3'-sulfoxide diastereomers (~9% of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (~4% of dose).
Slovenian: Biotransformacija emtricitabina vključuje oksidacijo tiolnega dela molekule, pri čemer nastanejo 3'-sulfoksid diastereomere (~ 9 % odmerka) in konjugacijo z glukuronsko kislino, pri čemer nastane 2'-O-glukuronid (~ 4 % odmerka).
English: Renal excretion of intact tenofovir alafenamide is a minor pathway with < 1% of the dose eliminated in urine.
Slovenian: Ledvično izločanje nespremenjenega tenofoviralafenamida je manj pomembna pot z < 1 % odmerka, izločenega v urinu.
English: In some patients with advanced liver disease or cirrhosis, stopping treatment may lead to worsening of hepatitis, which may be life-threatening.
Slovenian: Pri nekaterih bolnikih z napredovalim obolenjem jeter ali cirozo prenehanje zdravljenja lahko povzroči poslabšanje hepatitisa, ki je lahko življenjsko nevarno.
English: • If you notice within 18 hours of the time you usually take Descovy, you must take the tablet as soon as possible.
Slovenian: • Če to opazite v roku 18 ur od časa, ko zdravilo Descovy običajno vzamete, morate tableto vzeti čim prej.
English: On days of haemodialysis, Descovy should be administered after completion of haemodialysis treatment.
Slovenian: Ob dneh hemodialize je treba zdravilo Descovy dati po koncu zdravljenja s hemodializo.
English: However, tenofovir disoproxil fumarate reduced the viability index and weight of pups in a peri-postnatal toxicity study at maternally toxic doses.
Slovenian: Vendar pa je tenofoviralafenamidijev fumarat zmanjšal indeks viabilnosti in telesno maso mladičev v peri- in postnatalni študiji toksičnosti pri odmerkih, toksičnih za mater.
English: E/C/F/TAF demonstrated statistical superiority in achieving HIV-1 RNA < 50 copies/mL when compared to E/C/F/TDF at Week 144.
Slovenian: Zdravilo E/C/F/TAF je izkazalo statistično superiornost pri doseganju HIV-1 RNA < 50 kopij/ml v primerjavi z E/C/F/TDF v 144. tednu.
English: Following administration of tenofovir alafenamide, plasma [14C]-radioactivity showed a time-dependent profile with tenofovir alafenamide as the most abundant species in the initial few hours and uric acid in the remaining period.
Slovenian: Po dajanju tenofoviralafenamida je plazemska [14C]-radioaktivnost pokazala od časa odvisni profil, pri tem je bil tenofoviralafenamid najbolj zastopana vrsta radioaktivnosti v prvih nekaj urah in sečna kislina v preostalem obdobju.
English: Emtricitabine is rapidly and extensively absorbed following oral administration with peak plasma concentrations occurring at 1 to 2 hours post-dose.
Slovenian: Emtricitabin se po peroralni uporabi hitro in obsežno absorbira z največjimi koncentracijami v plazmi od 1 do 2 uri po odmerjanju.
English: It is important not to miss a dose of Descovy.
Slovenian: Pomembno je, da ne pozabite vzeti odmerka zdravila Descovy.
English: Treatment outcomes of Study GS-US-311-1089 through 48 and 96 weeks are presented in Table 6.
Slovenian: Izidi zdravljenja v študiji GS-US-311-1089 do vključno 48. tedna in 96. tedna so predstavljeni v preglednici 6.
English: • herbal remedies used to treat depression and anxiety containing: St. John's wort (Hypericum perforatum)
Slovenian: • zdravila rastlinskega izvora, ki se uporabljajo za zdravljenje depresije in tesnobe, ki vsebujejo: - šentjanževko (Hypericum perforatum)
English: b In both studies, patients were stratified by baseline HIV-1 RNA (≤ 100,000 copies/mL, > 100,000 copies/mL to ≤ 400,000 copies/mL, or > 400,000 copies/mL), by CD4+ cell count (< 50 cells/μL, 50-199 cells/μL, or ≥ 200 cells/μL), and by region (US or ex-US).
Slovenian: b V obeh študijah so bili bolniki stratificirani glede na začetno vrednost HIV-1 RNA (≤ 100.000 kopij/ml, > 100.000 kopij/ml do ≤ 400.000 kopij/ml ali > 400.000 kopij/ml), po številu celic CD4+ (< 50 celic/μl, 50-199 celic/μl ali ≥ 200 celic/μl) in po regiji (ZDA ali zunaj ZDA).
English: The frequencies were derived from Phase 3 E/C/F/TAF clinical studies in 866 treatment-naïve adult patients through 144 weeks of treatment (GS-US-292-0104 and GS-US-292-0111).
Slovenian: Pogostnosti so bile izpeljane iz kliničnih študij faze 3 z E/C/F/TAF pri 866 predhodno nezdravljenih odraslih bolnikih do vključno 144. tedna zdravljenja (GS-US-292-0104 in GS-US-292-0111).
English: Overall, 22% had baseline plasma HIV-1 RNA > 100,000 copies/mL.
Slovenian: Celokupno je imelo 22 % začetno plazemsko HIV-1 RNA > 100.000 kopij/ml.
English: Table 2: Interactions between the individual components of Descovy and other medicinal products
Slovenian: Preglednica 2: Interakcije med posameznimi učinkovinami zdravila Descovy in drugimi zdravili Učinkovine po terapevtskih področjih1
English: Descovy should be avoided in patients with estimated CrCl ≥ 15 mL/min and < 30 mL/min, or < 15 mL/min who are not on chronic haemodialysis, as the safety of Descovy has not been established in these populations.
Slovenian: Zdravilu Descovy se je treba izogniti pri bolnikih z ocenjenim CrCl ≥ 15 ml/min in < 30 ml/min ali < 15 ml/min, ki niso na kronični hemodializi, saj varnosti zdravila Descovy pri teh populacijah niso dokazali.
English: Emtricitabine systemic exposure was unaffected when emtricitabine was administered with food.
Slovenian: Dajanje emtricitabina s hrano ni vplivalo na sistemsko izpostavljenost emtricitabinu.
English: Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1) (see sections 4.2 and 5.1).
Slovenian: Zdravilo Descovy je indicirano v kombinaciji z drugimi protiretrovirusnimi učinkovinami za zdravljenje odraslih in mladostnikov (starih 12 let in več s telesno maso vsaj 35 kg), okuženih z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1) (glejte poglavji 4.2 in 5.1).
English: Tenofovir alafenamide exposure is expected to decrease when tipranavir/ritonavir is used in combination with Descovy.
Slovenian: Pričakuje se, da se bo izpostavljenost tenofoviralafenamidu pri uporabi tipranavirja/ritonavirja v kombinaciji z zdravilom Descovy zmanjšala.
English: Do not stop taking Descovy without talking to your doctor: see section 3, Do not stop taking Descovy.
Slovenian: Ne prenehajte jemati zdravila Descovy, ne da bi se pogovorili z zdravnikom: glejte poglavje 3,
English: No dose adjustment of norgestimate/ethinylestradiol is required.
Slovenian: Odmerka norgestimata/etinilestradiola ni treba prilagajati.
English: • If you notice 18 hours or more after the time you usually take Descovy, then do not take the missed dose.
Slovenian: • Če to opazite po 18 urah ali več od časa, ko običajno vzamete zdravilo Descovy, pozabljenega odmerka ne vzemite.
English: 102.4 (38.9)b
Slovenian: 102,4 (38,9)b n/v n/v
English: The safety profile in patients with mild to moderate renal impairment was similar to that in patients with normal renal function (see section 5.1).
Slovenian: Varnostni profil zdravila Descovy pri bolnikih z blago do zmerno ledvično okvaro je bil podoben kot pri bolnikih z normalnim delovanjem ledvic (glejte poglavje 5.1).
English: Although kidney problems have not been observed with Descovy, there is a possibility that you may experience kidney problems when taking Descovy over a long period of time.
Slovenian: Čeprav pri zdravilu Descovy niso opazili težav z ledvicami, obstaja možnost, da boste med dolgotrajnim jemanjem zdravila imeli težave z ledvicami.
English: The mean age was 58 years (range: 24-82), with 63 patients (26%) who were ≥ 65 years of age.
Slovenian: Povprečna starost je bila 58 let (razpon: 24-82), s 63 bolniki (26 %), starimi ≥ 65 let.
English: There are no data available to make dosing recommendations for co-administration with other protease inhibitors.
Slovenian: Ni podatkov za priporočila o odmerjanju pri sočasnem dajanju z drugimi zaviralci proteaze.
English: Darunavir, cobicistat and emtricitabine/tenofovir disoproxil fumarate (n = 50)
Slovenian: Darunavir, kobicistat in emtricitabin/ dizoproksiltenofovirijev fumarat (n = 50)
English: Of the patients who were HBsAg positive at baseline, 3/70 (4.3%) achieved seroconversion to anti-HBs Week 48.
Slovenian: Med bolniki, ki so bili ob izhodišču HBsAg pozitivni, so 3/70 (4,3 %) dosegli serokonverzijo na anti-HBs v 48. tednu.
English: Table 1: Dose of Descovy according to third agent in the HIV treatment regimen
Slovenian: Preglednica 1: Odmerek zdravila Descovy glede na tretjo učinkovino v režimu zdravljenja HIV Odmerek zdravila Descovy Tretje zdravilo v režimu zdravljenja HIV
English: Following administration of food in healthy subjects, peak plasma concentrations were observed approximately 1 hour post-dose for tenofovir alafenamide administered as F/TAF (25 mg) or E/C/F/TAF (10 mg).
Slovenian: Po dajanju hrane zdravim prostovoljcem so najvišje plazemske koncentracije opazili približno 1 uro po odmerku tenofoviralafenamida, uporabljenega kot F/TAF (25 mg) ali E/C/F/TAF (10 mg).
English: In a study of virologically suppressed adult patients switching from abacavir/lamivudine to Descovy while maintaining the third antiretroviral agent (Study GS-US-311-1717), there were minimal changes in lipid parameters.
Slovenian: V študiji pri odraslih bolnikih z virološko supresijo, ki so prešli z abakavirja/lamivudina na zdravilo Descovy, pri čemer so obdržali tretje protiretrovirusno zdravilo (študija GS-US-311-1717), so opazili minimalne spremembe v parametrih lipidov.
English: A minimal infiltration of histiocytes was present in the eye in dogs at tenofovir alafenamide and tenofovir exposures of approximately 4 and 17 times greater, respectively, than those expected after administration of Descovy.
Slovenian: Minimalna infiltracija histiocitov je bila prisotna v očesu psov pri izpostavljenosti tenofoviralafenamidu in tenofovirju, ki je bila približno 4-krat oz. 17-krat večja od pričakovane po dajanju zdravila Descovy.
English: Do not stop taking Descovy
Slovenian: Ne prenehajte jemati zdravila Descovy
English: At Week 48, the median percentage change in urine retinol binding protein to creatinine ratio was 4% in the Descovy group and 16% in those remaining on an abacavir/lamivudine containing regimen; and in urine beta-2 microglobulin to creatinine ratio it was 4% vs. 5%.
Slovenian: V 48. tednu je mediana odstotkovne spremembe razmerja med vezavnim proteinom za retinol v urinu in kreatininom znašala 4 % v skupini, ki je prejemala zdravilo Descovy in 16 % pri tistih, ki so nadaljevali z režimom, ki je vseboval abakavir/lamivudin, medtem ko sta mediani spremembe v razmerju med beta-2 mikroglobulinom v urinu in kreatininom znašali 4 % oziroma 5 %.
English: Descovy blocks the action of the reverse transcriptase enzyme, which is essential for the virus to multiply.
Slovenian: Zdravilo Descovy blokira delovanje encima reverzne transkriptaze, ki je nujen za razmnoževanje virusa.
English: Do not breast-feed during treatment with Descovy.
Slovenian: Med zdravljenjem z zdravilom Descovy ne dojite.
English: In vitro Reduced susceptibility to emtricitabine is associated with M184V/I mutations in HIV-1 RT.
Slovenian: Zmanjšana občutljivost za emtricitabin je povezana z mutacijami M184V/I pri HIV-1 RT.
English: Co-administration of emtricitabine with medicinal products that are eliminated by active tubular secretion may increase concentrations of emtricitabine, and/or the co-administered medicinal product.
Slovenian: Sočasno dajanje emtricitabina z zdravili, ki se izločajo z aktivnim tubularnim izločanjem, lahko zviša koncentracije emtricitabina in/ali sočasno uporabljenih zdravil.
English: Discontinuation of Descovy therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis.
Slovenian: Descovy pri bolnikih s hkratno okužbo s HIV in virusom HBV je lahko povezana s hudimi akutnimi poslabšanji hepatitisa.
English: At the start of treatment with E/C/F/TAF, the 72 patients had been HIV-suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months with or without suppression of HBV DNA and had compensated liver function.
Slovenian: Na začetku zdravljenja z E/C/F/TAF je imelo 72 bolnikov vsaj 6 mesecev supresijo HIV (HIV-1 RNA < 50 kopij/ml) s supresijo HBV DNA ali brez nje in kompenzirano jetrno funkcijo.
English: There were no clinically significant changes in fasting lipid laboratory tests in patients who switched.
Slovenian: Klinično pomembnih sprememb v laboratorijskih preiskavah lipidov na tešče pri bolnikih, ki so zdravilo zamenjali, ni bilo.
English: Baseline viral load ≤ 100,000 copies/mL > 100,000 copies/mL
Slovenian: ≤ 100.000 kopij/ml > 100.000 kopij/ml
English: Other protease inhibitors
Slovenian: Drugi zaviralci proteaze
English: In a separate Phase 1 study of emtricitabine alone, mean systemic emtricitabine exposure was higher in patients with severe renal impairment (estimated CrCl < 30 mL/min) (33.7 μg•h/mL) than in subjects with normal renal function (11.8 μg•h/mL).
Slovenian: V ločeni študiji 1. faze samo z emtricitabinom je bila povprečna sistemska izpostavljenost emtricitabinu večja pri bolnikih s hudo okvaro ledvic (ocenjeni CrCL < 30 ml/min) (33,7 µg•h/ml) kot pri preskušancih z normalnim delovanjem ledvic (11,8 µg•h/ml).
English: Emtricitabine did not inhibit the glucuronidation reaction of a non-specific UGT substrate in vitro.
Slovenian: Emtricitabin in vitro ni zaviral glukuronidacijske reakcije na nespecifične substrate UGT.
English: If a patient misses a dose of Descovy by more than 18 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.
Slovenian: Če bolnik izpusti odmerek zdravila Descovy za več kot 18 ur, naj ne nadomesti izpuščenega odmerka in preprosto nadaljuje z jemanjem po običajnem režimu odmerjanja.
English: In vitro binding of tenofovir to human plasma proteins is < 0.7% and is independent of concentration over the range of 0.01-25 μg/mL.
Slovenian: In vitro je bila vezava tenofovirata na humane plazemske proteine < 0,7 % in je neodvisna od koncentracije v razponu med 0,01-25 μg/ml.
English: Descovy in combination with other medicines is for the treatment of human immunodeficiency virus 1 (HIV-1) infection in adults and adolescents 12 years of age and older, who weigh at least 35 kg.
Slovenian: Zdravilo Descovy v kombinaciji z drugimi zdravili je namenjeno zdravljenju okužbe z virusom človeške imunske pomanjkljivosti 1 (HIV-1) pri odraslih in mladostnikih, starih 12 let in več, s telesno maso vsaj 35 kg.
English: Multinucleoside-resistant HIV-1 with a T69S double insertion mutation or with a Q151M mutation complex including K65R showed reduced susceptibility to tenofovir alafenamide.
Slovenian: Proti multinukleozidu rezistenten HIV-1 z dvojno insercijsko mutacijo T69S ali mutacijskim kompleksom Q151M, vključno s K65R, je pokazal zmanjšano občutljivost za tenofoviralafenamid.
English: No dose adjustment of Descovy is required in adults with end stage renal disease (estimated CrCl < 15 mL/min) on chronic haemodialysis; however, Descovy should generally be avoided but may be used in these patients if the potential benefits are considered to outweigh the potential risks (see sections 4.4 and 5.2).
Slovenian: Odmerka zdravila Descovy pri odraslih s končno ledvično odpovedjo (ocenjeni CrCl < 15 ml/min) na kronični hemodializi ni treba prilagoditi; vendar pa se je treba zdravilu Descovy načeloma izogniti, a se lahko uporablja pri teh bolnikih, če prevlada mnenje, da so možne koristi večje od možnih tveganj (glejte poglavji 4.4 in 5.2).
English: < 20 copies/mL
Slovenian: < 50 kopij/ml
English: emtricitabine and tipranavir
Slovenian: - emtricitabin in tipranavir
English: Tenofovir alafenamide is permeable into cells and due to increased plasma stability and intracellular activation through hydrolysis by cathepsin A, tenofovir alafenamide is more efficient than tenofovir disoproxil fumarate in concentrating tenofovir in peripheral blood mononuclear cells (PBMCs) or HIV target cells including lymphocytes and macrophages.
Slovenian: Tenofoviralafenamid prodira v celice in zaradi večje stabilnosti v plazmi in aktivacije v celici s hidrolizo s pomočjo katepsina A je tenofoviralafenamid bolj učinkovit kot dizoproksiltenofovirijev fumarat pri koncentriranju tenofovirja v mononuklearnih celicah v periferni krvi (peripheral blood mononuclear cells, PBMC) ali drugih ciljnih celicah HIV, vključno z limfociti in makrofagi.
English: Do not stop taking Descovy without talking to your doctor.
Slovenian: Ne prenehajte jemati zdravila Descovy, ne da bi se posvetovali z zdravnikom.
English: Hepatic impairment No dose adjustment of Descovy is required in patients with hepatic impairment.
Slovenian: Odmerka zdravila Descovy ni treba prilagoditi pri bolnikih z jetrno okvaro.
English: In animal studies there were no effects of emtricitabine and tenofovir alafenamide on mating or fertility parameters (see section 5.3).
Slovenian: V študijah na živalih ni bilo učinkov emtricitabina ali tenofoviralafenamida na parjenje ali parametre plodnosti (glejte poglavje 5.3).
English: Tenofovir alafenamide is transported by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).
Slovenian: Tenofoviralafenamid se prenaša s P-glikoproteinom (P-gp) in proteinom, odpornim na raka dojke (BCRP, Breast Cancer Resistance Protein).
English: If you take more than the recommended dose of Descovy you may be at higher risk of side effects of this medicine (see section 4, Possible side effects).
Slovenian: Če ste vzeli večji odmerek zdravila Descovy, kot bi smeli Če ste zaužili odmerek zdravila Descovy, višji od priporočenega, obstaja večje tveganje za neželene učinke (glejte poglavje 4, Možni neželeni učinki).
English: At baseline, 30% of patients were receiving abacavir/lamivudine in combination with a boosted protease inhibitor and 70% of patients were receiving abacavir/lamivudine in combination with an unboosted third agent.
Slovenian: Ob izhodišču je 30 % bolnikov prejemalo abakavir/lamivudin v kombinaciji z okrepljenim zaviralcem proteaze, 70 % bolnikov pa abakavir/lamivudin v kombinaciji z neokrepljenim tretjim zdravilom.
English: Fluconazole Isavuconazole
Slovenian: flukonazol izavukonazol